NASDAQ: ANTXAn2 Therapeutics Inc Stock Ownership - Who owns An2 Therapeutics?
Insider buying vs selling
Have An2 Therapeutics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Sarah Joanne Williams | Principal Accounting Officer | 2026-03-03 | 327 | $1.06 | $346.62Sell |
| Stephen David Prior | Chief Strategy Officer | 2026-01-06 | 2,858 | $1.01 | $2.89kSell |
| Sanjay Chanda | Chief Development Officer | 2026-01-06 | 5,956 | $1.01 | $6.03kSell |
| Joshua M. Eizen | Chief Operating Officer and Chief Legal Officer | 2026-01-06 | 6,931 | $1.01 | $7.01kSell |
| Lucy Day | Chief Financial Officer | 2026-01-06 | 5,512 | $1.01 | $5.58kSell |
| Sanjay Chanda | Chief Development Officer | 2026-01-05 | 3,295 | $1.00 | $3.30kSell |
| Lucy Day | Chief Financial Officer | 2026-01-05 | 3,295 | $1.00 | $3.30kSell |
| Joshua M. Eizen | Chief Operating Officer and Chief Legal Officer | 2026-01-05 | 17,923 | $1.00 | $17.94kSell |
| Stephen David Prior | Chief Strategy Officer | 2026-01-05 | 3,604 | $1.00 | $3.61kSell |
| Stephen David Prior | Chief Strategy Officer | 2025-11-04 | 765 | $1.14 | $872.10Sell |
ANTX insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when ANTX insiders and whales buy or sell their stock.
ANTX Shareholders
What type of owners hold An2 Therapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Kabeer Aziz | 14.66% | 5,280,796 | $23.66M | Insider |
| Adjuvant Global Health Technology Fund LP | 13.87% | 4,994,638 | $22.38M | Insider |
| Ra Capital Management LP | 11.31% | 4,074,370 | $18.25M | Insider |
| Braden Michael Leonard | 8.93% | 3,217,432 | $14.41M | Insider |
| Vivo Capital LLC | 8.76% | 3,153,640 | $14.13M | Institution |
| Commodore Capital LP | 6.48% | 2,333,713 | $10.46M | Institution |
| Millennium Management LLC | 6.17% | 2,222,502 | $9.96M | Institution |
| Eric Easom | 4.89% | 1,759,801 | $7.88M | Insider |
| Spruce Street Capital LP | 4.61% | 1,661,073 | $7.44M | Institution |
| Almitas Capital LLC | 4.11% | 1,479,129 | $6.63M | Institution |
ANTX vs Biotech Stocks
An2 Therapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.